NCT04222842 is a Phase 1 clinical trial of CM082 in Myopic Choroidal Neovascularisation, sponsored by AnewPharma.

Who is sponsoring NCT04222842?

NCT04222842 is sponsored by AnewPharma.

What drugs are being tested in NCT04222842?

Interventions in NCT04222842: CM082.

What condition does NCT04222842 study?

NCT04222842 studies Myopic Choroidal Neovascularisation.

Is NCT04222842 still recruiting?

NCT04222842 is currently suspended. Last updated 10 March 2021.

Last reviewed 2021-03-10 · How we verify

NCT04222842

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

CM082 in Patients With Myopic Choroidal Neovascularization (CNV)

Suspended Phase 1 Last updated 10 March 2021

What this trial tests

Phase 1 trial testing CM082 in Myopic Choroidal Neovascularisation in 96 participants. Suspended.

Timeline

18 December 2019

Primary endpoint
30 December 2021

30 December 2021

Quick facts

Lead sponsor	AnewPharma
Phase	Phase 1
Status	Suspended
Study type	INTERVENTIONAL
Allocation	na
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	96
Start date	18 December 2019
Primary completion	30 December 2021
Estimated completion	30 December 2021
Sites	1 location across China

Drugs / interventions tested

CM082 — full drug profile →

Conditions studied

Myopic Choroidal Neovascularisation — all drugs for Myopic Choroidal Neovascularisation →

Sponsor

AnewPharma — full company profile →

Who can join

Adults 18 to 50, any sex, with Myopic Choroidal Neovascularisation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Intermittent Oral Dosing of CM082 tablets in Chinese Patients With mCNV.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of CM082

Trials testing the same drug.

NCT03710863 — Safety and Tolerability of Oral CM082 in Patients With wAMD · Phase 2 · unknown

Other AnewPharma trials

Trials by the same sponsor.

NCT04434326 — The Absorption, Metabolism and Excretion of [14C]CM082 in Human · Phase 1 · completed
NCT04328506 — Bioequivalency Study of CM082 Tablet in Healthy Volunteers · Phase 1 · completed
NCT04126668 — A Study to Investigate the Food Effect on the Pharmacokinetics of CM082 Tablet in Chinese Healthy Volunteers · Phase 1 · completed
NCT03904719 — CM082 and JS001 in Patients With Advanced Small-cell Lung Cancer (SCLC) · Phase 2 · unknown
NCT03710863 — Safety and Tolerability of Oral CM082 in Patients With wAMD · Phase 2 · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04222842 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by AnewPharma
Last refreshed: 10 March 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04222842.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing